Pharma Pulse: Flu Vaccination Rates Improve, AI Powers RNA Therapeutics, and Statin Intolerance Spurs Self-Medication Risks

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re highlighting encouraging progress in flu vaccination rates, a new AI-driven partnership in RNA therapeutics, and concerns about how patients are managing statin intolerance.

• New data show that influenza vaccination rates have increased among Black, Hispanic, and older adult populations—groups historically under-vaccinated compared to the general public. Public health experts attribute the gains to targeted outreach, improved community engagement, and expanded access through pharmacies and local clinics. While overall flu vaccination coverage still has room to grow, the results are a positive sign that tailored interventions can help close gaps and protect vulnerable populations against seasonal influenza.
• In biotech news, Circurna and GATC Health have announced a partnership to apply artificial intelligence to the discovery of circular RNA-based therapies. Circular RNAs, known for their stability and durability in cells, are gaining attention as a next-generation therapeutic modality. By combining Circurna’s expertise in RNA technology with GATC’s AI-driven discovery platform, the collaboration aims to accelerate the identification of new treatments across multiple disease areas. This reflects the growing convergence of AI and biotechnology in driving future therapeutic breakthroughs.
• Lastly, a new study reveals that many patients who report statin intolerance are turning to self-medication, despite little evidence that alternatives reduce LDL cholesterol levels effectively. Researchers warn that patients substituting or discontinuing therapy without guidance risk poorer cardiovascular outcomes. The findings highlight the need for better patient education, closer provider follow-up, and expanded use of validated treatment options for those struggling with statin-related side effects.

From improving flu vaccination access to AI-powered innovation and addressing gaps in cardiovascular care, these stories show the diverse challenges and opportunities shaping healthcare today.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.